BioCentury
ARTICLE | Top Story

Insmed proposes $60M follow-on

July 16, 2013 12:50 AM UTC

Insmed Inc. (NASDAQ:INSM) proposed late Monday to raise $60 million in a follow-on underwritten by Leerink; Lazard; and Canaccord. In 1H14, Insmed plans to submit regulatory applications to EMA and Health Canada for Arikace amikacin to treat Pseudomonas aeruginosa infection in cystic fibrosis (CF) patients. The company reported mixed results from the Phase III CLEAR-108 trial of the inhaled liposomal amikacin last month. Insmed gained Arikace through its 2010 acquisition of Transave Inc. (see BioCentury Extra, July 1). ...